START Midwest
Midwest
Grand Rapids, MI
Not yet accepting
S227928
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
- Antibody Drug Conjugate (ADC)
- MCL-1 Inhibitor
- CD74
- Phase 1/2